Linked Life Data

19031176

Source:http://linkedlifedata.com/resource/pubmed/id/19031176

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-12-22
pubmed:abstractText
We retrospectively determined the efficacy and safety of a combination of bevacizumab and irinotecan in a consecutive series of 52 heavily pre-treated patients with recurrent high-grade brain tumours. Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) and 125 mg/m(2) for those not receiving EIAEDs] every 2 weeks. Fifty-two patients were included and 47 were evaluable for response.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1651-226X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
52-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
pubmed:affiliation
Department of Oncology, Finsencenter, Rigshospitalet, Copenhagen, Denmark. Hans.Skovgaard.Poulsen@rh.regionh.dk
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't